简单的语言摘要:CROWN研究的5年结果,罗拉提尼布与克里佐提尼布在非小细胞肺癌中对比
Benjamin J Solomon1, Geoffrey Liu2, Enriqueta Felip3
1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Future oncology (London, England)
|October 3, 2024
概括
洛拉提尼布在5年内显著改善了与crizotinib相比,在晚期ALK阳性NSCLC患者中没有癌症进展的生存率. 虽然洛拉提尼布的严重副作用率较高,但它在预防大脑转移方面的有效性更高.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 晚期非小细胞肺癌 (NSCLC) 往往呈现出形淋巴瘤激酶 (ALK) 基因变异.
- 改变ALK基因驱动瘤生长,并可能导致转移.
- 先进的ALK阳性NSCLC的第一线治疗选择对于患者的治疗结果至关重要.
研究的目的:
- 为了比较洛拉提尼布与克里佐替尼布在先前未接受治疗的患有晚期ALK阳性NSCLC的患者中的疗效和安全性.
- 评估长期结果,包括5年的随访后的无进展生存率和中枢神经系统 (CNS) 转移.
- 评估与两种药物相关的副作用的发生率和严重程度.
主要方法:
- CROWN研究是一项第三期临床试验,比较了lorlatinib和crizotinib.
- 参与者患有晚期ALK阳性NSCLC,并且没有接受过先前的治疗.
- 结果在平均5年的随访期内进行评估,重点关注无进展生存率,中枢神经系统进展和不良事件.
主要成果:
- 5年后,60%的洛拉提尼布患者在没有癌症进展的情况下活着,而克里佐替尼布的患者只有8%.
- 与crizotinib相比,洛拉提尼布显著降低了癌症向大脑的传播.
- 严重或危及生命的副作用更常见于洛拉提尼布 (77%) 比克里佐提尼布 (57%).
结论:
- 与crizotinib相比,lorlatinib在先进的ALK阳性NSCLC的第一线治疗中显示出更高的长期疗效.
- 洛拉提尼布的5年效益,特别是在预防中枢神经系统转移方面,代表了治疗的重大进步.
- 虽然副作用的概况有所不同,但延长生存的好处支持洛拉提尼布在管理这种患者群体中的作用.
关键词:
五年业绩 五年业绩这是一种ALK抑制剂.皇冠 皇冠 皇冠临床试验临床试验临床试验临床试验临床试验克里佐丁尼布 (crizotinib) 的使用方法洛拉提尼布 (lorlatinib) 是一种药物.非小细胞肺癌的肺癌.简单的语言简要概要.更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
